Mineralys Therapeutics (MLYS) Earnings Date & Reports
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
MLYS is expected to report earnings to rise 45.45% to -95 cents per share on November 11
Q3'25
Est.
$-0.96
Q2'25
Beat
by $0.40
Q1'25
Beat
by $0.29
Q4'24
Missed
by $0.27
Q3'24
Missed
by $0.42
The last earnings report on August 12 showed earnings per share of -66 cents, beating the estimate of -105 cents. With 4.56M shares outstanding, the current market capitalization sits at 1.91B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MLYS showed earnings on August 12, 2025. You can read more about the earnings report here.